just googling they had high SVRs in good prognosis gen-1 pts
Russian regulators may have already signed-off on Sofo/PegRiba based on postive outcomes in the U.S. and Europe. Perhaps this study will determine whether the combo can be labeled for use without interferon. The idea of bringing a questionable oral combo to market, without an interferon-based option (which can only be superior in efficacy), makes no sense.
JQ if this was your line of thinking, sorry I missed it. The idea of pushing into Russia still seems to go against GILD's original strategy. Let's wait for confirmation on this.
Market Data 
Markets 
AI
